2.25 USD
-0.56 (-19.93%)
At close: Jan 30, 2026
2.22 USD
-0.03 (-1.33%)
After Hours: 1/30/2026, 8:00:01 PM
DRMA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. DRMA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DRMA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year DRMA has reported negative net income.
- DRMA had a negative operating cash flow in the past year.
- DRMA had negative earnings in each of the past 5 years.
- DRMA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -174.46%, DRMA is doing worse than 87.05% of the companies in the same industry.
- DRMA's Return On Equity of -223.42% is on the low side compared to the rest of the industry. DRMA is outperformed by 70.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -174.46% | ||
| ROE | -223.42% | ||
| ROIC | N/A |
ROA(3y)-194.6%
ROA(5y)-241.76%
ROE(3y)-356.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- DRMA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- DRMA has more shares outstanding than it did 1 year ago.
- DRMA has more shares outstanding than it did 5 years ago.
- DRMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- DRMA has an Altman-Z score of -23.11. This is a bad value and indicates that DRMA is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of DRMA (-23.11) is worse than 84.57% of its industry peers.
- DRMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -23.11 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 4.56 indicates that DRMA has no problem at all paying its short term obligations.
- The Current ratio of DRMA (4.56) is comparable to the rest of the industry.
- A Quick Ratio of 4.56 indicates that DRMA has no problem at all paying its short term obligations.
- With a Quick ratio value of 4.56, DRMA perfoms like the industry average, outperforming 54.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.56 | ||
| Quick Ratio | 4.56 |
3. Growth
3.1 Past
- DRMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.70%, which is quite impressive.
EPS 1Y (TTM)82.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 40.71% on average over the next years. This is a very strong growth
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.68%
EPS Next 2Y40.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- DRMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRMA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- DRMA's earnings are expected to grow with 40.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.71%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- DRMA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
DERMATA THERAPEUTICS INC / DRMA FAQ
What is the ChartMill fundamental rating of DERMATA THERAPEUTICS INC (DRMA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to DRMA.
What is the valuation status for DRMA stock?
ChartMill assigns a valuation rating of 1 / 10 to DERMATA THERAPEUTICS INC (DRMA). This can be considered as Overvalued.
Can you provide the profitability details for DERMATA THERAPEUTICS INC?
DERMATA THERAPEUTICS INC (DRMA) has a profitability rating of 0 / 10.
Can you provide the financial health for DRMA stock?
The financial health rating of DERMATA THERAPEUTICS INC (DRMA) is 6 / 10.
Can you provide the expected EPS growth for DRMA stock?
The Earnings per Share (EPS) of DERMATA THERAPEUTICS INC (DRMA) is expected to grow by 94.68% in the next year.